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ABSTRACT HIV viral load (VL) testing is the recommended method for monitor-
ing the response of people living with HIV and receiving antiretroviral therapy
(ART). The availability of standard plasma VL testing in low- and middle-income
countries (LMICs), and access to this testing, are limited by the need to use fresh
plasma. Good specimen collection methods for HIV VL testing that are applicable
to resource-constrained settings are needed. We assessed the diagnostic perfor-
mance of the ﬁltered dried plasma spot (FDPS), created using the newly devel-
oped, instrument-free VLPlasma device, in identifying treatment failure at a VL
threshold of 1,000 copies/ml in fresh plasma. Performance was compared with
that of the conventional dried blood spot (DBS). Venous blood samples from 201
people living with HIV and attending an infectious disease clinic in Malaysia
were collected, and HIV VL was quantiﬁed using fresh plasma (the reference
standard), FDPS, and DBS specimens. VL testing was done using the Roche Co-
bas AmpliPrep/Cobas TaqMan v2.0 assay. At a threshold of 1,000 copies/ml, the
diagnostic performance of the FDPS was superior (sensitivity, 100% [95% conﬁ-
dence interval {CI}, 89.1 to 100%]; speciﬁcity, 100% [95% CI, 97.8 to 100%]) to
that of the DBS (sensitivity, 100% [95% CI, 89.4 to 100%]; speciﬁcity, 36.8% [95%
CI, 29.4 to 44.7%]) (P 0.001). A stronger correlation was observed between the
FDPS VL and the plasma VL (r 0.94; P 0.001) than between the DBS VL and
the plasma VL (r 0.85; P 0.001). The mean difference in VL measures be-
tween the FDPS and plasma (plasma VL minus FDPS VL) was 0.127 log10 cop-
ies/ml (standard deviation [SD], 0.32), in contrast to –0.95 log10 copies/ml (SD,
0.84) between the DBS and plasma. HIV VL measurement using the FDPS outper-
formed that with the DBS in identifying treatment failure at a threshold of 1,000
copies/ml and compared well with the quantiﬁcation of VL in plasma. The FDPS
can be an attractive alternative to fresh plasma for improving access to HIV VL
monitoring among people living with HIV on ART in LMICs.
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The World Health Organization recommends HIV-1 RNA viral load (VL) testing as thepreferred method for monitoring the response to antiretroviral therapy (ART) in
people living with HIV (1). Routine VL testing can support ART adherence (2) and
enables early detection of treatment failure (3, 4). Existing evidence suggests that
increasing the coverage of VL testing could (i) prolong sensitivity to ﬁrst-line ART
regimens, (ii) reduce the development of drug resistance in susceptible individuals, (iii)
reduce the frequency of clinic visits required for disease monitoring in virally sup-
pressed individuals, and (iv) increase the effectiveness and efﬁcacy of treatment
programs globally (5, 6). However, in many low- and middle-income countries (LMICs),
access to and use of VL testing are still limited due to the complexity of specimen
collection, storage, and transportation to central laboratories and the requirement for
expensive laboratory equipment and highly trained personnel (7).
The dried blood spot (DBS) can be used as an alternative sample type to plasma for
improving access to VL testing in LMICs (8). The use of DBS can simplify sample
collection as well as transportation issues and can reduce the cost of VL testing by
removing the need for cold-chain systems. DBSs can be stable for as long as 6 months
at ambient temperature before testing (9). However, DBSs may have low sensitivity due
to low sample volume (50 to 100 l of whole blood) and low speciﬁcity in identifying
treatment failure using the 1,000-copies/ml threshold due to the inclusion of white
blood cells and associated viral RNA and proviral DNA (10). The reduced accuracy of the
DBS for VL testing has limited its potential in expanding VL testing to all people living
with HIV on ART in resource-constrained settings. Therefore, there is a need for
technological innovation to improve the diagnostic accuracy of VL testing in resource-
constrained settings.
A newly developed instrument-free, disposable, and easy-to-use sample collection
and preparation device—the VLPlasma blood separation device—separates the plasma
component from a whole-blood sample (100 l) without the need for a centrifuge. This
is a prototype product, fully manufactured by Nanjing BioPoint Diagnostics (Nanjing,
People’s Republic of China) under ISO13485/2016 certiﬁcation for study purposes. The
device comprises a ﬁlter paper strip assembly that recovers cell-free plasma from whole
blood using lateral ﬂow principles, housed within a cartridge that protects the sample
during drying and transport. Details of the development and evaluation of the lateral
ﬂow separation technique have been reported elsewhere (11). The plasma sample is
dried and stored within the VLPlasma device cartridge, and the ﬁlter containing the
dried plasma (known as the ﬁltered dried plasma spot [FDPS]) is then transferred
directly to a sample tube for VL testing, as an alternative to the DBS.
This study assessed the diagnostic accuracy of FDPSs, collected using the VLPlasma
device, in the measurement of HIV-1 RNA VLs and the detection of VLs of 1,000
copies/ml, using fresh plasma specimens as the reference standard. We also compared
the performance of FDPS with that of DBS for VL testing among people living with HIV
and receiving ART at an infectious disease clinic in Kuala Lumpur, Malaysia.
MATERIALS AND METHODS
This was a prospective diagnostic accuracy study. Each study participant provided 12 ml of venous
blood collected in EDTA tubes for the preparation of fresh plasma, DBS, and FDPS samples. Three VL tests
were carried out for each participant, and clinical decisions were based on the results of VL tests carried
out on fresh plasma as part of the standard of care. HIV-1 RNA VLs were measured using the Roche Cobas
AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (CAP/CTM), system, one of the most commonly used HIV VL
testing platforms in low- and middle-income countries (12) with acceptable accuracy (13).
Participants. People aged 18 years and older living with HIV and attending the Infectious Disease
Clinic, University Malaya Medical Centre, were consecutively recruited and invited to participate in the
study. To be eligible, study participants had to have documented and conﬁrmed HIV infection, be eligible
for VL testing as part of the standard of care, and be currently taking ART at the study site with at least
one of the following: (i) documented virological failure (deﬁned as having two consecutive VL measure-
ments exceeding 1,000 copies/ml) at previous visits during the past 6 months, (ii) documented immu-
nological failure (deﬁned as having a CD4 count below the baseline CD4 level or a persistent CD4 count
below 100 cells/mm3), (iii) clinical failure (deﬁned as having a new or recurrent clinical event indicating
severe immunodeﬁciency, WHO clinical stage 4) in previous visits during the past 6 months, or (iv)
documented self-reported nonadherence (deﬁned as having missed 2 doses of medication) in the past
4 weeks. Participants also had to be able and willing to provide written informed consent.
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Sample size. Based on our previous laboratory evaluation (11), the expected sensitivity (and
speciﬁcity) of the FDPS in detecting samples with VLs at a cutoff of 1,000 copies/ml was at least 90%.
Using formulae of sample size calculation for diagnostic test accuracy studies (14) with a marginal error
(the difference between the estimates and the true value that is expected to be detected or one-half of
the desired width of the conﬁdence interval) of 0.05 and an estimated prevalence of treatment failure
(VL, 1,000 copies/ml) at the study site of 20%, the required sample size was 173. With an expected
response rate of at least 90%, the ﬁnal sample size required for the study was 190.
Plasma preparation. Upon arrival at the laboratory (within 6 h of blood collection), 3 ml of
EDTA–whole blood was centrifuged at 3,200 rpm for 20 min, and plasma aliquots were stored in sterile
tubes at –4°C. The tubes were labeled with deidentiﬁed participant information for VL testing within 24
h of blood collection according to the standard operating procedure at the study site.
FDPS preparation. FDPS samples were prepared by a trained research laboratory staff member
using a VLPlasma device (see Picture S1 in the supplemental material) in the following steps: (i) 100 l
of EDTA-blood was transferred to the sample cavity of the device using a calibrated pipette; (ii) after 3
min of incubation, 90 l of phosphate-buffered saline (PBS) was added to the sample cavity by use of the
plastic pipette and buffer provided with the VLPlasma device; (iii) the device was left to dry overnight at
room temperature before being packaged into a ziplock bag with four desiccant sachets and a humidity
indicator. FDPS samples were stored as long as 81 days at room temperature before testing.
DBS preparation. The same research staff member who prepared the FDPS sample also prepared
the DBS sample. A 700-l volume of EDTA-blood was spotted onto two Whatman no. 903 Protein Saver
cards (Whatman plc, Little Chalfont, Buckinghamshire, UK) using a calibrated pipette, each containing
ﬁve DBSs (70 l for each DBS). The card was dried overnight and was then packaged and stored by the
same procedure as that for the FDPS samples.
HIV RNA VL quantiﬁcation. Plasma specimens were tested on the Roche CAP/CTM platform (Roche
Diagnostics Ltd., Risch-Rotkreuz, Switzerland) at the viral diagnostic laboratory, University of Malaya,
Malaysia, a center that participates in the College of American Pathologists quality assurance program.
Plasma VL tests were carried out following the HI2CAP protocol developed by Roche Diagnostics for HIV
VL testing using EDTA-plasma samples (15). The sample volume was 1.0 ml with a reportable VL range
of 20 to 10,000,000 copies/ml as per the manufacturer’s instructions. Matched FDPS and DBS specimens
were tested on the same Roche CAP/CTM platform using the HI2DFS protocol (Roche Diagnostics Ltd.,
Risch-Rotkreuz, Switzerland) speciﬁed for testing dried ﬂuid samples and with a lower limit of quantiﬁ-
cation of 400 copies/ml. A single DBS cut from the card, or a plasma ﬁlter pad removed from the device,
was placed in a sample tube (S-tube), to which was added 1 ml of guanidinium-based specimen
pre-extraction reagent (SPEX; provided by Roche Diagnostics). The tube was then placed in a thermo-
mixer (Eppendorf AG, Hamburg, Germany) for 10 min at 56°C for continuous shaking at 1,000 rpm.
Nucleic acids were extracted using the automated Cobas AmpliPrep instrument and were then trans-
ferred to the Cobas TaqMan analyzer for ampliﬁcation and quantiﬁcation.
Data management and analysis. Data were collected using predeveloped data collection forms
documenting participants’ age, gender, duration on ART, and eligibility status. HIV VL test results (FDPS,
DBS, and fresh plasma) were recorded separately for each sample taken and tested. All data were entered
and stored in the REDCap electronic data capture tool (Vanderbilt University, Nashville, TN, USA) hosted
at the Burnet Institute (16).
The diagnostic performance of the FDPS was assessed by calculating sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value (NPV) in identifying treatment failure at a threshold
of 1,000 copies/ml—the current WHO-recommended virological failure threshold—in relation to the
plasma reference standard for the VL. The diagnostic performance of the DBS was assessed identically to
the performance of the FDPS. Kappa scores were used to assess diagnostic agreement between the index
(FDPS or DBS) and the reference (plasma) method at a cutoff of 1,000 copies/ml.
For continuous outcomes (quantitative HIV-1 RNA VL measurements, reported as numbers of copies
per milliliter), Pearson statistics and linear regression analyses were used to assess correlations between
paired VL results (FDPS VL versus plasma VL and DBS VL versus plasma VL). Concordances (agreements)
between FDPS and plasma VLs and between DBS and plasma VLs were assessed using Bland-Altman (BA)
analysis (17) and Lin’s concordance correlation coefﬁcient (pc) (18). The BA analysis evaluates the mean
difference between measurements with the index method and measurements with the reference
method (calculated as plasma VL minus FDPS VL or plasma VL minus DBS VL) and estimates the limits
of agreement (LOAs), within which 95% of the differences fall. The closer the mean difference is to zero
(perfect agreement) and the narrower the width of the 95% LOAs, the better the agreement between the
two methods. The pc quantiﬁes the agreement between the two measures of the same variable (VL); pc
values range from 1 to 1, with perfect agreement at 1.
A volume correction factor of 1.97 was applied for quantitative FDPS VLs (400 copies/l). This
correction factor was the average of the ratio of the plasma VLs to the corresponding quantitative FDPS
VLs (n 32). As per the manufacturer’s package insert instructions (19), no correction factor was applied
for DBS VLs on the Roche CAP/CTM platform.
All analyses were performed using STATA statistical software (version 15.0; StataCorp, College Station,
TX). Signiﬁcance levels were set at an  value of 0.05.
Ethics. This study received ethics approval from the Medical Research Ethics Committee of the
University of Malaya, Kuala Lumpur, Malaysia (no. 20161021-4399) and the Ethics Committee of The
Alfred Hospital, Melbourne, Australia (no. 478/16).
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From June 2017 to May 2018, a total of 201 people living with HIV on ART who met
the inclusion criteria and provided written consent were enrolled into the study. Three
patients did not have index VL tests (FDPS and DBS) done (Fig. 1 and 2). (Figures 1 and
2 are STARD [Standard for Reporting of Diagnosis Accuracy Studies] ﬂow diagrams [20].)
FIG 1 Flow diagram of FDPS VL test performance at a cutoff of 1,000 copies/ml according to STARD guidelines. The asterisk indicates
that three FDPS samples failed to provide a valid viral load result on the Roche Cobas AmpliPrep/Cobas TaqMan platform.
FIG 2 Flow diagram of DBS VL test performance at a cutoff of 1,000 copies/ml according to STARD guidelines. The asterisk
indicates that two DBS samples failed to provide a valid viral load result on the Roche Cobas AmpliPrep/Cobas TaqMan
platform.
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The mean age of the remaining 198 patients was 41.7 years (standard deviation [SD],
10.3 years; range, 21 to 69 years), with a median duration on ART of 36 months
(interquartile range [IQR], 12 to 84 months). Among 198 participants who had three VL
tests each (plasma VL, FDPS VL, DBS VL) done, 3 did not have valid FDPS VL results and
2 did not have valid DBS VL results. This left 195 participants with paired plasma
VL–FDPS VL results and 196 participants with paired plasma VL–DBS VL results for
analysis (Fig. 1 and 2; see also Table S1 in the supplemental material). Reported plasma
VLs ranged from ND (VL not detected) to 1,593,975 copies/ml, while the reported FDPS
VLs ranged from ND to 1,530,634 copies/ml, and the reported DBS VLs ranged from ND
to 1,440,221 copies/ml.
Diagnostic accuracy of the FDPS for VL assessment. At a cutoff of 1,000 copies/
ml, agreement between FDPS VLs and plasma VLs was 100% (n 195) (Fig. 1).
Sensitivity, speciﬁcity, positive predictive value (PPV), and negative predictive value
(NPV) in identifying treatment failure using FDPS were 100% (95% conﬁdence interval
[CI], 89.1% to 100%), 100% (95% CI, 97.8% to 100%), 100% (95% CI, 89.1% to 100%), and
100% (95% CI, 97.8% to 100%), respectively. The kappa score for the measurement of
agreement between FDPS VLs and plasma VLs was 1.000 (95% CI, 1.000 to 1.000).
In the comparison of diagnostic agreement between FDPS VLs and plasma VLs as
continuous measurement, we found that of 198 participants, 32 had quantiﬁable VL
results on both the FDPS and the plasma samples (plasma VL, 20 copies/ml; FDPS VL,
400 copies/ml). Pearson correlation and linear regression showed a strong, positive
correlation between FDPS VLs and plasma VLs (r 0.94; P 0.001; n 32) (Fig. 3). BA
analysis showed a positive mean difference of 0.127 (SD, 0.31) log10 copies/ml between
FDPS and plasma VL results and 95% limits of agreement (LoAs) of 0.48 to 0.74 log10
copies/ml (Fig. 4). Lin’s concordance correlation coefﬁcient for the FPDS was 0.927.
Diagnostic accuracy of the DBS for VL assessment. At a cutoff of 1,000 copies/ml,
the agreement between DBS VLs and plasma VLs was 47% (95% CI, 40.5% to 54.4%)
(n 196) (Fig. 2). The sensitivity, speciﬁcity, PPV, and NPV of the DBS were 100% (95%
CI, 89.4% to 100%), 36.8% (95% CI, 29.4% to 44.7%), 24.3% (95% CI, 17.3% to 32.4%),
and 100% (95% CI, 94.0% to 100%), respectively. The kappa score for the measurement
of agreement between DBS VLs and plasma VLs was 0.164 (95% CI, 0.103 to 0.225).
For the comparison of continuous measurements, 95 patients had quantitative VL
results with paired DBS–plasma samples. Pearson correlation and linear regression
analyses showed a positive correlation (r 0.85; P 0.001; n 95) (Fig. 5). BA analysis
showed an overestimation of VLs for the DBS (relative to plasma), with a mean
difference of0.95 (SD, 0.84) log10 copies/ml and LoAs of2.60 to 0.71 log10 copies/ml
(Fig. 6). Lin’s concordance correlation coefﬁcient for the DBS was 0.581.
FIG 3 Correlation between paired VL results obtained from FDPS and plasma specimens, measured in
log10 copies per milliliter (n 32). Pearson correlation coefﬁcient (r), 0.94; P 0.001.
Performance of VLPlasma Device for HIV VL Testing Journal of Clinical Microbiology
April 2019 Volume 57 Issue 4 e01683-18 jcm.asm.org 5
 o
n






Detailed data on the diagnostic performance of the FDPS and DBS are presented in
Tables S1 to S4 in the supplemental material.
DISCUSSION
In this study, we evaluated the performance of a novel plasma separation device and
method providing a ﬁltered dried plasma sample to allow easy transport of a plasma
sample to the laboratory for HIV VL testing. Using a virological failure threshold of 1,000
copies/ml, the current WHO-recommended cutoff for diagnosis of treatment failure, we
observed perfect (100%) agreement between FDPS and plasma results. We found that
the FDPS outperforms the DBS in identifying virological failure among people living
with HIV on ART by use of the Roche CAP/CTM system. The DBS misclassiﬁed 53%
(103/196) of patients as “failing treatment,” requiring unnecessarily close monitoring,
additional adherence consultation, conﬁrmatory VL testing, and switching of treat-
ments. This ﬁnding is in line with ﬁndings from prior studies of the DBS for HIV VL
testing. A systematic review of 43 studies comparing DBS and plasma specimens for VL
testing, based on which WHO recommended the use of the DBS for VL monitoring at
a threshold of 1,000 copies/ml, reported pooled estimates of sensitivity and speciﬁcity
for the Roche CAP/CTM assay (SPEX protocol) of 99% (95% CI, 97 to 100%) and 44%
FIG 4 Bland-Altman plot demonstrating agreement between FPDS and plasma VL results, measured in
log10 copies per milliliter (n 32). The mean difference (purple line) was 0.127 (SD, 0.31) log10 copies/ml,
and the 95% limits of agreement (red lines) were –0.48 to 0.74 log10 copies/ml.
FIG 5 Correlation between paired VL results obtained from DBS and plasma samples, measured in log10
copies per milliliter (n 95). Pearson correlation coefﬁcient (r), 0.85; P 0.001.
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(95% CI, 18 to 74%), respectively. When used in different assays/protocols (Roche
CAP/CTM FVE protocol, Abbott RealTime assay, bioMérieux NucliSens test, Biocentric
Charge Virale, Siemens kPCR), the DBS produces higher speciﬁcity (range, 55 to 95%)
but lower sensitivity (range, 84 to 95%) (8).
Quantitatively, while strong and positive correlation with plasma was found for both
the FDPS and the DBS by Pearson’s correlation analysis, Bland-Atman analysis results
showed that FDPS had much better agreement with a much smaller bias (0.13 versus
0.95 log copies/ml), and a narrower limit of agreement (0.48 to 0.74 versus 2.60
to 0.71 log copies/ml); furthermore, all samples were within the limit of agreement.
Better performance of the FDPS was conﬁrmed by Lin’s concordance analysis, with a
concordance coefﬁcient (pc) of 0.93 versus 0.58 for the DBS (a pc value of 1 is a perfect
concordance).
We observed an overall underestimation of HIV-RNA VLs with the FDPS relative to
levels for corresponding plasma specimens. This could be explained by the differences
in the volume of specimen used. The FDPS used 100 l of whole blood, while HIV RNA
was measured in 1 ml of the fresh plasma sample. Even though the Roche CAP/CTM
system has incorporated a correction in the HI2DFS testing protocol for dried ﬂuid
samples, this could still be a source of bias for HIV RNA quantiﬁcation with FDPS
samples. To compensate for the volume difference, for samples with quantitative FDPS
VL results (400 copies/ml), we applied a correction factor of 1.97. This was calculated
on the basis of results of only 32 paired FDPS–plasma samples with quantitative VLs on
the Roche CAP/CTM system. Given different sample handling/processing procedures, as
well as different techniques in HIV RNA ampliﬁcation and quantiﬁcation across com-
mercially available VL testing platforms, this correction factor is likely to be altered in
future studies validating the performance of the FDPS on different VL platforms and
with a larger sample size.
There are some limitations that should be taken into consideration in interpreting
the ﬁndings of this study. First, in our study sample, the treatment failure rate using a
threshold of 1,000 copies/ml was 17%, with plasma VLs ranging from undetectable to
6.2 log10 copies/ml. While this failure rate falls within the range of virological failure
rates of people living with HIV on ART reported from other studies in resource-
constrained settings, the virological failure rate in LMICs could be as high as 30% for
patients at higher levels of viremia (21, 22). We were unable to assess the performance
of the FDPS in samples with plasma VLs of 6 log10 copies/ml—a common scenario
among ART-naïve patients who present late in care. Second, we had only 32 paired
FDPS–plasma samples with quantitative VL results, which was about the minimum
FIG 6 Bland-Altman plot demonstrating agreement between DBS and plasma VL results, measured in
log10 copies per milliliter (n 95). The mean difference (purple line) was –0.95 (SD, 0.84) log10 copies/ml,
and the LoAs (red lines) were –2.60 to 0.71 log10 copies/ml.
Performance of VLPlasma Device for HIV VL Testing Journal of Clinical Microbiology
April 2019 Volume 57 Issue 4 e01683-18 jcm.asm.org 7
 o
n






sample size required for an assessment of agreement between two methods of
measurement using Bland-Altman analysis (23). We were unable to perform subanaly-
ses of these samples to provide further insights into the performance of the FDPS
compared to plasma quantitatively (continuous measurement of HIV VL). Third, in this
study, we used venous blood samples collected by a trained clinical staff. Since
venipuncture may not be feasible and/or practical at clinics in resource-constrained
settings, and there are potential differences between the diagnostic performance of
dried ﬂuid samples prepared from venous blood and those prepared from capillary
blood (24), further study is needed to assess the performance of the FDPS using ﬁnger
pricks by health care professionals at the point of care.
In conclusion, we observed excellent diagnostic accuracy for the FDPS, in the hands
of highly trained clinical and laboratory staff, in detecting treatment failure at a cutoff
of 1,000 copies/ml. There were a strong correlation and excellent agreement between
FDPS and plasma VL results obtained from venous blood samples on the Roche
CAP/CTM platform. This is in stark contrast to the low speciﬁcity observed with the DBS.
Our study ﬁndings show that the FDPS could potentially be an alternative specimen to
fresh plasma for HIV VL monitoring in LMICs. Further study assessing the diagnostic
performance of the FDPS, using capillary blood samples in a clinic setting with a larger
sample size, is warranted.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/JCM
.01683-18.
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